Beta-1,4-N-acetyl-galactosaminyltransferase 1 (B4GALNT1)

Beta-1,4-N-acetyl-galactosaminyltransferase 1 (B4GALNT1) is a glycosyltransferase enzyme localized to the Golgi apparatus that catalyzes the transfer of N-acetylgalactosamine (GalNAc) to specific substrates, producing the gangliosides GM2 and GD2 from GM3 and GD3, respectively[3][9]. These gangliosides are important glycolipids predominantly found on neural tissues and melanocytes, with roles in cell–cell recognition, signal transduction, and modulation of cell motility[1][2][9]. B4GALNT1 is essential for the synthesis of complex brain gangliosides, and mutations or loss of function lead to severe neurological diseases such as hereditary spastic paraplegia[4][2]. Overexpression of B4GALNT1 correlates with increased malignancy in tumors like melanoma and neuroblastoma, likely through changes in ganglioside patterns that promote anchorage-independent growth and cell migration[1][7][10]. The protein is a type-II membrane protein and forms constitutive dimers in membranes, processing lipid substrates efficiently[6]. While no approved drugs currently target B4GALNT1 directly, therapeutic research is ongoing to modulate its activity in cancers and neurological diseases, and ganglioside products GM2 and GD2 serve as disease biomarkers[1][9].

Other names

GalNAc-TGM2 synthaseGM2/GD2 synthasebeta-1,4-GalNAc transferase 1

Inhibition of GM2/GD2 biosynthesis, Modulation of ganglioside-mediated signaling pathways